Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I
Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA.
Mov Disord. 1996 May;11(3):321-3. doi: 10.1002/mds.870110317.
We performed a 6-month open-label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD). Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS), and standardized neuropsychological measures. Adverse events (AEs) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, although four subjects reported mild AEs, including headache, heartburn, fatigue, and increased involuntary movements. There was no significant effect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in long-term clinical trials designed to slow the progression of HD.
我们进行了一项为期6个月的开放标签试验，以评估辅酶Q10（CoQ）对10例亨廷顿舞蹈症（HD）患者的耐受性和疗效。在基线、3个月和6个月时，使用HD评定量表（HDRS）、HD功能能力量表（HDFCS）和标准化神经心理学测量方法对受试者进行评估。每月通过电话访谈评估不良事件（AE）。CoQ剂量范围为每天600至1200毫克。所有受试者均完成了研究，尽管有4名受试者报告了轻度不良事件，包括头痛、烧心、疲劳和不自主运动增加。治疗对临床评分没有显著影响。CoQ的良好耐受性表明，它是在旨在减缓HD进展的长期临床试验中进行评估的良好候选药物。
